Form 4: Bank of America Entities Divest ENvue Medical Shares

Bank of America and its subsidiaries reported significant sales of ENvue Medical, Inc. common stock on February 2, 2026.

Summary

• Bank of America Corporation, BofA Securities, Inc., and Bank of America NA, identified as 10% owners and directors, jointly filed a Form 4.
• The reporting persons disposed of a total of 233,948 shares of ENvue Medical, Inc. common stock through multiple transactions on February 2, 2026.
• Transaction prices for the disposed shares ranged from $2.3000 to $3.0700 per share.
• Following these transactions, the beneficial ownership of common stock by the reporting persons decreased from an initial 233,956 shares to 8 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• The reporting persons explicitly stated that any profit potentially recoverable by the Issuer under Section 16(b) of the Exchange Act, if they were deemed greater than 10% beneficial owners and the transactions were subject to Section 16(b), has been or will be remitted to the Issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for ENvue Medical, Inc. given the significant divestment by a major institutional shareholder, which often signals reduced confidence or a strategic exit.

Positives

• The reporting persons indicated that any short-swing profits potentially recoverable by ENvue Medical, Inc. under Section 16(b) will be remitted to the Issuer, which is a positive for the company's shareholders.

Negatives

• Significant insider selling by a 10% owner and director group can be perceived as a negative signal regarding the company's future prospects or valuation.
• The beneficial ownership of common stock by Bank of America entities in ENvue Medical, Inc. decreased substantially from 233,956 shares to 8 shares.

Risks

• The filing mentions the potential for short-swing profit recovery under Section 16(b) of the Exchange Act if the reporting persons were deemed greater than 10% beneficial owners and the transactions were subject to this section.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding ENvue Medical, Inc.'s future performance or outlook.

Management Comments

• Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer of (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
• Without conceding its status as a greater than 10% beneficial owner or that the reported transactions are subject to disclosure under Section 16(a) of the Exchange Act or short-swing profit recovery under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that the Reporting Persons were greater than 10% beneficial owners and the transactions were subject to Section 16(b) has been or will be remitted to the Issuer.

Industry Context

StockSavvy.ai notes that this Form 4 filing primarily reflects an institutional investor's portfolio management decision rather than a direct commentary on broader industry trends. However, significant divestment by a major financial institution could be interpreted by the market as a lack of confidence in the specific company or its sector, potentially influencing investor sentiment.

Corporate Governance

Legal Proceedings

• The filing acknowledges the possibility of short-swing profit recovery under Section 16(b) of the Exchange Act, stating that any such recoverable profit will be remitted to the Issuer.

Related Party Transactions

• Bank of America holds an indirect interest in the securities through its subsidiaries, BANA and BOFAS, which are also reporting persons in this joint filing.

Stakeholder Impact

• Shareholders may view the significant selling by a major institutional investor as a negative indicator, potentially leading to decreased investor confidence and downward pressure on the stock price.
• The Issuer (ENvue Medical, Inc.) may benefit from the remittance of any short-swing profits, as stated in the filing, if applicable.

Key Dates

Recommendation

The extensive selling by a major institutional investor and 10% owner, Bank of America entities, signals a lack of confidence or a strategic exit from ENvue Medical, Inc. Such a significant divestment by a sophisticated investor typically precedes or accompanies downward price movement, making a 'sell' recommendation prudent for investors to mitigate potential losses or reallocate capital.

Keywords

ENvue Medical, FEED, Bank of America, Insider Selling, Form 4, Stock Disposition, 10b5-1 Plan, Beneficial Ownership, SEC Filing